Erratum

The new kid on the block(ade) of the IGF-1 receptor

In this Preview (Cancer Cell 5, pp. 201–202), the authors mistakenly described the administration of NVP-AEW541 in the accompanying article by García-Echeverría et al. (Cancer Cell 5, 231–239) as being subcutaneous instead of oral. This is an important point since it underscores the oral availability of this compound. Therefore, the sentence on page 202, line 9, should read: “Mouse 3T3 fibroblasts overexpressing the human IGF-1R form tumors in nude mice, and oral administration of NVP-AEW541 inhibited the growth of these tumors.”

Derek LeRoith* and Lee Helman
Diabetes Branch, NIDDK
Pediatric Oncology Branch, NCI
Bethesda, Maryland 20892
*Correspondence: derek@helix.nih.gov